Anthony Wong

University of California, San Francisco — United States

Medicine · Health Sciences

24h-index3.7kcitations161works1.22yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Prostate Cancer Treatment and Research(32), Prostate Cancer Diagnosis and Treatment(28), Bladder and Urothelial Cancer Treatments(19), Computational Drug Discovery Methods(14), Advanced Radiotherapy Techniques(12)

Publications159 total

FORMULA-509: A Multicenter Randomized Trial of Postprostatectomy Salvage Radiotherapy and 6 months of a GNRH Agonist with Either Bicalutamide or Abiraterone Acetate plus Prednisone and Apalutamide
European Urology·2026Open Access
Survey on the availability, labeling, and pricing of salt-free/reduced packaged foods and table salt alternatives in Klang Valley, Malaysia
Discover Food·2025Open Access
Natural language processing for deep phenotyping of patients receiving genomic testing enables effective gene prioritization in a clinical diagnostics pipeline
Journal of Pathology Informatics·2025Open Access
Prognostic Impact of Lymph Node Yield in a Phase III Clinical Trial (NRG/RTOG 9601) of Prostate Cancer Patients Treated With Salvage Radiation Following Prostatectomy
The Prostate·2025Open Access
Circulating tumor DNA (ctDNA) monitoring in patients (pts) with advanced urothelial carcinoma (aUC) treated with enfortumab vedotin +/- pembrolizumab (EVP).
Journal of Clinical Oncology·2025· 2 cited
RMP-YOLO: A Robust Motion Predictor for Partially Observable Scenarios Even if You Only Look Once
2025· 2 cited
Availability, Labeling, and Pricing of Salt-Free/Reduced Packaged Foods and Table Salt Alternatives: A Survey in Klang Valley, Malaysia
2025Open Access
P683: Natural language processing for deep phenotyping of patients receiving genomic testing enables effective gene prioritization in a clinical diagnostics pipeline
Genetics in Medicine Open·2025Open Access
Testosterone Recovery and Associated Impact on Patient-Reported Health-Related Quality of Life (HRQoL) after Treatment with 6 Months of GnRH Agonist with or without Abiraterone Acetate plus Prednisone (AAP) and Apalutamide (Apa) in the FORMULA-509 Trial
International Journal of Radiation Oncology*Biology*Physics·2024Open Access
Inter- and Intra-Observer Variability in Catheter Localization in High-Dose-Rate Brachytherapy for Prostate Cancer with Stepping Transverse and Twister Sagittal Volume Scanning
International Journal of Radiation Oncology*Biology*Physics·2024
Long-Term Patient-Reported Health-Related Quality of Life in the Randomized FORMULA-509 Trial of Salvage Radiotherapy and 6 Months of GnRH Agonist with Either Bicalutamide or Abiraterone Acetate Plus Prednisone and Apalutamide after Radical Prostatectomy
International Journal of Radiation Oncology*Biology*Physics·2024· 1 cited
ControlMTR: Control-Guided Motion Transformer with Scene-Compliant Intention Points for Feasible Motion Prediction
2024· 5 cited
RMP-YOLO: A Robust Motion Predictor for Partially Observable Scenarios even if You Only Look Once
arXiv (Cornell University)·2024Open Access
Delayed definitive management of localized prostate cancer: what do we know?
Prostate Cancer and Prostatic Diseases·2024· 3 citedOpen Access
DRAMA: An Efficient End-to-end Motion Planner for Autonomous Driving with Mamba
arXiv (Cornell University)·2024· 2 citedOpen Access
Intensification of ADT with enzalutamide in high-risk patients with biochemical relapse following radical prostatectomy undergoing salvage radiation: Initial results from RTOG 3506 (STEEL).
Journal of Clinical Oncology·2024· 1 cited
ControlMTR: Control-Guided Motion Transformer with Scene-Compliant Intention Points for Feasible Motion Prediction
arXiv (Cornell University)·2024Open Access
Abstract 4988: Responders to combination radiation and PD-1 blockade demonstrate reduced myeloid immunosuppression and enhanced interferon signaling in oligometastatic prostate cancer patients
Cancer Research·2024
Patient-reported health-related quality of life (HRQoL) in the randomized FORMULA-509 trial of salvage radiotherapy and 6 months of GnRH agonist with either bicalutamide or abiraterone acetate plus prednisone (AAP) and apalutamide (Apa) after radical prostatectomy (RP).
Journal of Clinical Oncology·2024· 1 cited
Intensification of ADT with enzalutamide in high-risk patients with biochemical relapse following radical prostatectomy undergoing salvage radiation: Initial results from RTOG 3506 (STEEL).
Journal of Clinical Oncology·2024· 8 cited
page 1 of 8Next →

Frequent Co-authors

Felix Y. Feng(8), Sima P. Porten(8), Jonathan Chou(8), Eric J. Small(8), Peter R. Carroll(8), James G. Christensen(7), Arpita Desai(6), Lawrence Fong(6), Terence W. Friedlander(6), Vadim S. Koshkin(6), Matthew R. Cooperberg(6), Rahul Aggarwal(6), Kartik Chandran(5), Daniel E. Spratt(5), Paul L. Nguyen(5), Daniel H. Kwon(5), Emily Chan(5), Ming Qiu(4), Cathy C. Zhang(4), Zhengming Yan(4)